Cargando…
Long noncoding RNA MALAT1 knockdown reverses chemoresistance to temozolomide via promoting microRNA‐101 in glioblastoma
Glioblastoma (GBM) is the most common and lethal tumor of the central nervous system with highly infiltrative and resistant to chemotherapy. Temozolomide (TMZ) is widely used as the first‐line treatment for the therapy of GBM. However, a considerable percentage inherent or acquired resistance in GBM...
Autores principales: | Cai, Tao, Liu, Yu, Xiao, Jie |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5911628/ https://www.ncbi.nlm.nih.gov/pubmed/29479863 http://dx.doi.org/10.1002/cam4.1384 |
Ejemplares similares
-
MicroRNA-101 reverses temozolomide resistance by inhibition of GSK3β in glioblastoma
por: Tian, Tian, et al.
Publicado: (2016) -
MicroRNA profiling of Chinese primary glioblastoma reveals a temozolomide-chemoresistant subtype
por: Yan, Wei, et al.
Publicado: (2015) -
Long noncoding RNA LINC01410 promotes the tumorigenesis of neuroblastoma cells by sponging microRNA‐506‐3p and modulating WEE1
por: Mi, Jie, et al.
Publicado: (2020) -
Long noncoding RNA MALAT1 regulates HDAC4‐mediated proliferation and apoptosis via decoying of miR‐140‐5p in osteosarcoma cells
por: Sun, Yuxiu, et al.
Publicado: (2018) -
MicroRNA‐124: An emerging therapeutic target in cancer
por: Jia, Xinqi, et al.
Publicado: (2019)